Dendritic cells pulsed with an anti-idiotype antibody mimicking Her-2/neu induced protective antitumor immunity in two lines of Her-2/neu transgenic mice
/in Breast Cancer, Dendritic Cells, International Publications /von 2010-02-24 / Cell. Immunol. 2010;263(1):9-21Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma
/in Dendritic Cells, International Publications, Malignant Pleural Mesothelioma /von 2010-02-18 / Am. J. Respir. Crit. Care Med. 2010 Jun;181(12):1383-90Ovarian cancer immunotherapy: opportunities, progresses and challenges
/in International Publications, Ovarian Cancer /von 2010-02-10 / J Hematol Oncol 2010 Feb;3:7Potent anti-tumor responses to immunization with dendritic cells loaded with tumor tissue and an NKT cell ligand
/in Dendritic Cells, International Publications /von 2010-02-09 / Immunol. Cell Biol. 2010 Jul;88(5):596-604The anti-tumor effect of Newcastle disease virus HN protein is influenced by differential subcellular targeting
/in International Publications, Newcastle Disease Virus /von 2010-02-04 / Cancer Immunol. Immunother. 2010 Jul;59(7):989-99Multicenter, phase 3 trial comparing selenium supplementation with observation in gynecologic radiation oncology
/in International Publications, Micronutrients /von 2010-02-03 / Int J Radiat Oncol Biol Phys 2010 Nov;78(3):828-35Generation of tumor-specific T lymphocytes using dendritic cell/tumor fusions and anti-CD3/CD28
/in Dendritic Cells, International Publications /von 2010-02-01 / J. Immunother. 2010 Feb-Mar;33(2):155-66
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution